Experience

Elucida Oncology, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Scientific Officer

  • Aug 2019 - 4 years 5 months

  Princeton, New Jersey Elucida Oncology is a clinical stage company developing targeted ultra-small C'-dot (nanoparticle) Drug Conjugates (CDCs) for the treatment of cancer. Our CDCs build upon the successes of antibody drug conjugate (ADC) technology and address the limitations of ADCs by delivering payloads deep into tumors and accessing tumors in difficult to target locations like the brain.



Integral Molecular

• United States
• Biotechnology Research
• 1 - 100 Employee

• Scientific Advisory Board Member

  • Jun 2015 - 8 years 7 months

  Greater Philadelphia Area



Sesen Bio

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Scientific Officer

  • Jan 2017 - Mar 2019

  Cambridge, MA, USA Note: Eleven Bio changed its name to Sesen Bio in May of 2018. As CSO I focused on guiding the development of the product line of sesen bio (Eleven Bio) which is primarily focused on antibody-based fusion proteins containing potent toxins capable of killing dividing and non-dividing cancer cells. My role included identification of new technologies for in licensing, establishing strategic collaborations and moving leads into clinical trials. I was also part of the team working on… Show more Note: Eleven Bio changed its name to Sesen Bio in May of 2018. As CSO I focused on guiding the development of the product line of sesen bio (Eleven Bio) which is primarily focused on antibody-based fusion proteins containing potent toxins capable of killing dividing and non-dividing cancer cells. My role included identification of new technologies for in licensing, establishing strategic collaborations and moving leads into clinical trials. I was also part of the team working on securing additional financial investment into Eleven Biotherapeutics, presenting the company to bankers, analysts and investment groups as the need arises. Show less



Eleven Biotherapeutics

• Chief Development Officer

  • Sep 2016 - Jan 2017

  Greater Philadelphia Area Following the acquisition of Viventia by Eleven Biotherapeutics I joined the management team of Eleven as the Chief Development Officer. My position was focused on guiding the development of the product line including identification of new technologies for in licensing, establishing strategic collaborations and moving leads into clinical trials. I was part of the team working on Securing additional financial investment into Eleven Biotherapeutics, presenting the company to bankers, analysts… Show more Following the acquisition of Viventia by Eleven Biotherapeutics I joined the management team of Eleven as the Chief Development Officer. My position was focused on guiding the development of the product line including identification of new technologies for in licensing, establishing strategic collaborations and moving leads into clinical trials. I was part of the team working on Securing additional financial investment into Eleven Biotherapeutics, presenting the company to bankers, analysts and investment groups. Show less



Viventia Bio Inc.

• Biotechnology Research
• 1 - 100 Employee

• Chief Development Officer

  • May 2015 - Sep 2016

  Greater Philadelphia Area I joined Viventia Bio as their Chief Development Officer in May of 2015. My evolving position is focused on guiding the development of the product line including identification of new technologies for in licensing, establishing strategic collaborations and moving leads into clinical trials. I am also part of the team working on Viventia's IPO and presenting the company to bankers, analysts and in testing the waters meetings with investment groups.

• Member: Scientific Advisory Board

  • 2001 - May 2015



Fox Chase Cancer Center

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Adjunct Associate Professor

  • May 2015 - May 2016

  Greater Philadelphia Area Adjunct Assoc. Professor in the Molecular Therapeutics Program at Fox Chase Cancer Center.

• Director of Biological Research and Therapeutics

  • Dec 2013 - May 2015

  Greater Philadelphia Area This position evolved from my prior role as a founder and Co-leader of the Developmental Therapeutics Program at the Fox Chase Cancer Center. One of my key goals in this position is to foster collaborations between Fox Chase Physicians and Scientists and their counterparts in pharma, biotech and other academic institutions that lead to the development of new biologic agents for the detection and treatment of cancer.

• Associate Professor

  • Jun 2008 - May 2015

  Tenured member of the faculty of the Developmental Therapeutics Program

• Tenured Faculty Member

  • 2008 - May 2015

  Lead a research group focused on developing antibody-based agents for the treatment of cancer.

• Co-Leader - Developmental Therapeutics Program

  • Jan 2009 - Dec 2013

  Co-leader of one of the five academic research programs (Departments) at Fox Chase Cancer Center in Philadelphia. The Developmental Therapeutics Program is a collaborative effort between basic science researchers and cancer physicians with expertise in clinical trials. We seek to understand the fundamental molecular events that drive cancer and exploit this knowledge in the development of novel therapeutics.


Temple University School of Medicine
• United States
• Higher Education
• 500 - 600 Employee
• Adjunct Associate Professor

  • Mar 2008 - 2016

Sevion Therapeutics
• Scientific Advisory Board Member

  • May 2014 - May 2015


RAbD Biotech

• United States
• Biotechnology Research
• 1 - 100 Employee

• CEO and Co-Founder

  • Jan 2014 - May 2015

  Hatboro, Pennsylvania Co-founder of RAbD Biotech LLC, a start up focused on rationally developing biotherapeutics including hormones and antibodies using knowledge of the 3D structure and sequence of the desired therapeutic target. We are using knowledge of protein structure and in silico design methods to design and produce agents that specifically bind to functional sites on receptors or other functional targets. Our primary focus is highly conserved sequences that are difficult to target using currently available… Show more Co-founder of RAbD Biotech LLC, a start up focused on rationally developing biotherapeutics including hormones and antibodies using knowledge of the 3D structure and sequence of the desired therapeutic target. We are using knowledge of protein structure and in silico design methods to design and produce agents that specifically bind to functional sites on receptors or other functional targets. Our primary focus is highly conserved sequences that are difficult to target using currently available methods. Our lead agent is RAD-003, a first-in-class biologic agent for the treatment of ovarian cancer. Show less


Mersana Therapeutics
• United States
• Biotechnology Research
• 100 - 200 Employee
• Scientific Advisory Board Member

  • Jan 2013 - May 2015


Symphogen

• Denmark
• Biotechnology Research
• 100 - 200 Employee

• Scientific Advisory Board Member

  • Oct 2011 - May 2015

  Copenhagen Area, Denmark Active member of the Symphogen SAB



Avid Biologics (Renamed Formation Biologics)

• Chief Scientific Advisor

  • Jan 2011 - May 2015

  Toronto, ON, Canada


Avipep
• Spain
• Member: Scientific Advisory Board

  • 2008 - May 2015

Endo Pharmaceuticals
• United States
• Pharmaceutical Manufacturing
• 300 - 400 Employee
• Oncology Advisory Board Member

  • May 2010 - Jun 2014


Teva Pharmaceuticals

• Israel
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Consultant

  • May 2014 - May 2014

  High-level consultation for Teva Pharmaceuticals on an in licensing / acquisition opportunity.



YM Biosciences

• Canada
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Scientific Advisory Board Member

  • Jun 2010 - Mar 2013

  Member of YM's SAB until it was acquired by Gilead Sciences, Inc.


Solixia
• India
• Real Estate
• Member: Scientific Advisory Board

  • 2008 - 2011


Woodcock Washburn LLP

• Law Practice
• 1 - 100 Employee

• Expert Witness

  • Oct 2008 - Jul 2009

  Served as an expert witness on behalf of Centocor in the Remicade vs Humira patent infringement lawsuit filed against Abbott Pharmaceuticals. Prepared and reviewed expert opinions on infringement, enablement, written description and testified in the jury trial in Marshall Texas.

• Associate Member

  • 2001 - 2008

• Assistant Member

  • Jun 1994 - 2001